Terns Pharmaceuticals Inc (NASDAQ:TERN) has a beta value of -0.14 and has seen 1.38 million shares traded in the recent trading session. The company, currently valued at $231.77M, closed the recent trade at $2.65 per share which meant it lost -$0.11 on the day or -3.80% during that session. The TERN stock price is -330.19% off its 52-week high price of $11.40 and -3.77% below the 52-week low of $2.75. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.85 million shares traded. The 3-month trading volume is 1.38 million shares.
The consensus among analysts is that Terns Pharmaceuticals Inc (TERN) is Buy stock at the moment, with a recommendation rating of 1.57. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 5 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.27.
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
Sporting -3.80% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TERN stock price touched $2.65 or saw a rise of 20.9%. Year-to-date, Terns Pharmaceuticals Inc shares have moved -52.08%, while the 5-day performance has seen it change -20.03%. Over the past 30 days, the shares of Terns Pharmaceuticals Inc (NASDAQ:TERN) have changed -21.68%. Short interest in the company has seen 5.95 million shares shorted with days to cover at 5.57.
Wall Street analysts have a consensus price target for the stock at $20, which means that the shares’ value could jump 86.75% from the levels at last check today. The projected low price target is $20.0 while the price target rests at a high of $20.0. In that case, then, we find that the latest price level in today’s session is -654.72% off the targeted high while a plunge would see the stock gain -654.72% from the levels at last check today.
Terns Pharmaceuticals Inc (TERN) estimates and forecasts
The company’s shares have lost -68.95% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 16.38% over the past 5 years. Earnings growth for 2025 is a modest -10.44% while over the next 5 years, the company’s earnings are expected to decrease by -12.26%.
TERN Dividends
Terns Pharmaceuticals Inc is expected to release its next earnings report on 2025-Mar-19 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
Insiders own 0.24% of the company shares, while shares held by institutions stand at 105.27% with a share float percentage of 105.52%. Investors are also buoyed by the number of investors in a company, with Terns Pharmaceuticals Inc having a total of 211.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 7.62 million shares worth more than $51.89 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 10.2326% of shares outstanding.
The other major institutional holder is VIVO CAPITAL, LLC, with the holding of over 6.18 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.11 million and represent 8.3038% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.37% shares in the company for having 2.07 shares of worth $5.55 million while later fund manager owns 1.83 shares of worth $4.89 million as of Feb 28, 2025, which makes it owner of about 2.09% of company’s outstanding stock.
